AlzeCure will present at the Pareto Securities 17th Annual Healthcare Conference in Stockholm on 2 September, with CEO Martin Jönsson scheduled to deliver a presentation and answer questions.
The presentation and one-on-one meetings are planned at Hotel At Six, Brunkebergstorg 6, with the company scheduling the session for 17:05-17:25 CEST and saying the presentation will be posted on its website after the event.
AlzeCure develops small-molecule drug candidates for central nervous system diseases with a focus on Alzheimer’s disease and pain and advances programmes across its NeuroRestore, Alzstatin and Painless platforms.
The company has recently signed collaboration and outlicensing agreements with Eli Lilly and with QuantumCell ApS. AlzeCure is listed on Nasdaq First North Premier Growth Market and uses FNCA Sweden AB as its Certified Adviser.
